While the government contract to date has been pro forma–the University of Mississippi/Oxford has won the contract every year since the late 1960s and MAPS’ and Prof. Lyle Craker’s successful lawsuit against the Drug Enforcement Administration (DEA) to effectively break Ol’ Miss’ monopoly on cultivating cannabis for research and approximately five Compassionate IND patients, and allow the University of Massachusetts/Amherst to cultivate research and therapeutic grade cannabis, is being appealed by DEA–competition can only help science, and the free market place of ideas and research.
In an attempt to clarify an apparent gaffe made a few weeks ago to California media stating that “marijuana is dangerous and has no medicinal value”, drug czar Gil Kerlikowske in a new interview with his hometown media in Seattle has only slightly, almost imperceptibly, modified his remarks by now implying that somehow how ‘smoked’ medical cannabis is not a legitimate and effective drug delivery method
Many years ago the former head of the U.S. National Institute on Drug Abuse (NIDA) Alan Leshner made this statement when forced to confront the fact that tens of thousands of patients were successfully using cannabis as a medicine:
“The plural of anecdote is not evidence.”
From today’s Washington Post’s Reliable Sources: It was only a matter of time before someone…
This informative article from CBS News about the government’s claim that there is no need for medical patients to access cannabis, when there is a ‘fake’ cannabis pill on the market, features remarks from NORML advisory board member, professor and author
Marijuana legalization is the hottest topic in the media these days. MSNBC, CNBC, CNN, FOX, NatGeo, and CBS News have presented special features on marijuana business, medical marijuana, and the marijuana legalization movement. Google Trends is showing double the interest in searches and news hits for the term “marijuana legalization”.
Now that more states are legalizing the sale of the marijuana used solely as a medicine, the next hurdle for reformers who say the drug is more cost-effective than pharmaceuticals is getting those who pay for health care—insurers and employers—to reimburse patients for its use.
For some 35 years the United States federal government has been well aware that cannabis possesses potent anti-cancer and anti-tumor properties. And for the past three years, government-funded researchers have speculated that these qualities may offer “protective” effects against the onset of various types of cancer in humans, including lung cancer.
